Sona Nanotech Inc. Announces Management Changes
member of the University of British Columbia's School of Biomedical Engineering's Industry Advisory Committee
and a member of the health policy council of the C.D. Mr. Fraser and Dr. Strapps are replacing Mr. Dan Whittaker and Mr. Robert McKay, who have both been long
serving members on the Company's Board, the former having served as chairman. Dr. Strapps was most recently Chief Scientific Officer of Gemini Therapeutics, a NASDAQ-listed biotech company.
Prior to that role, Dr. Strapps led Discovery at Intellia Therapeutics.